Section 22. Drug Screening

The program sponsor shall ensure that: A. staff members have knowledge of the benefits and limitations of laboratory drug detection tests and other toxicological testing procedures; B. a patient in comprehensive maintenance treatment receives at least eight random laboratory drug detection tests per year; short-term opioid treatment withdrawal procedure patients receive at least one initial drug abuse test; long-term opioid treatment withdrawal procedure patients receive an initial and monthly random tests; and other toxicological tests are performed according to written orders from the program medical director or medical practitioner designee; C. laboratory drug detection tests and other toxicological testing specimens are collected in a manner that minimizes falsification; D. laboratory drug detection tests for: (1) opioids; (2) methadone; (3) amphetamines; (4) cocaine; (5) barbiturates; (6) benzodiazepines; and (7) other substances as may be appropriate, based upon patient history and prevailing patterns of drug availability and use in the local area; 8.321.10 NMAC 10 E. the results of a patient’s laboratory drug detection tests or other toxicological test and any action taken relating to the results are documented in the patient record.